MECOM and ovarian serous adenocarcinoma: We recognize that while preclinical studies have shown that MECOM amplified tumors are sensitive to transcriptional targeted inhibitors in high grade serous ovarian cancer, there is a paucity of data in preclinical models of endometrial cancer.